Oral Sedation in Vitreoretinal Surgery
Macular Holes, Intraocular Lens Opacification, Vitrectomy
About this trial
This is an interventional treatment trial for Macular Holes focused on measuring Sedation during Vitreoretinal surgery, Oral Sedation, Anesthesia in Vitreoretinal Surgery, Oral Triazolam
Eligibility Criteria
Inclusion Criteria:
- Undergoing vitreoretinal surgery for a variety of indications including, but not limited to, epiretinal membrane (ERM), macular hole, vitreous opacities, vitreous hemorrhage, aphakia, dislocated or displaced intraocular or crystalline lens, silicone removal, endolaser, and retinal detachment.
- American Society of Anesthesiologists rating of I-III
Exclusion Criteria:
- Undergoing vitreoretinal surgery requiring general anesthesia
- Allergy or hypersensitivity to benzodiazepines
- Pregnant or nursing females
- Previous delirium after anesthesia
- Current use of drug or alcohol on the day of surgery
- Currently on medications inhibiting cytochrome P450
- Failed anesthesia clearance
- Reported anxiety or a history of anxiolytic use
- Vitreoretinal surgery performed within the last 3 months of the current procedure
- Impaired renal or liver function
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Oral Sedative
Intravenous Sedative
Participants will receive oral triazolam 30 minutes prior to surgery. Dose for BMI less than 35: 0.125 mg Dose for BMI greater than or equal to 35: 0.25 mg Followed by topical proparacaine and 6 cc sub-tenon's mixture of lidocaine and marcaine. Vitals will monitored by the operating room nurses.
This group will receive an intravenous sedative. The sedative is limited to midazolam, fentanyl, propofol. Follow by topical proparacaine and 6 cc sub-tenon's mixture of lidocaine and marcaine. IV and monitoring will be performed by anesthesiologist or CRNA.